Liver Directed Therapies for Metastatic Uveal Melanoma

Dr. Patel is an Associate Professor, Fellowship Program Director, and Director of the Uveal Melanoma Program in the Department of Melanoma Oncology at MD Anderson Cancer Center.  She is also Chair of the SWOG Melanoma Committee.

In these roles, she serves as lead physician for the uveal melanoma trials at MD Anderson including numerous investigator-initiated and sponsored clinical trials as well as Project 3 Co-Leader for the Melanoma SPORE.  She is also national Study Chair of SWOG S1801 and S1404 trials, the largest melanoma trials investigating neoadjuvant and adjuvant checkpoint blockade for cutaneous melanoma.

She has authored over 88 peer-reviewed manuscripts and book chapters, more than 28 as first or senior author.  Her grant work focuses on translational research, for which she has received at least 8 independent intramural and extramural funding awards as PI from the NIH/NCI, DOD, Melanoma SPORE, and MD Anderson Institutional Research Grants and Multidisciplinary Research Program award.  The goals of Dr. Patel’s work are to translate the findings into effective monitoring and therapeutic strategies for patients with melanoma. 

Dr. Eric Wehrenberg-Klee is an interventional radiologist at Massachusetts General Hospital in Boston, MA where he is the Director of the Center for Image-Guided Cancer Therapy, as well as an Assistant Professor of Radiology at Harvard Medical School.  He is the primary investigator on multiple investigator initiated and industry sponsored trials evaluating the role of minimally invasive interventional procedures for the treatment of cancer.  His laboratory work focus on the immune response to local tumor therapies and their synergy with checkpoint inhibition and is sponsored by grant funding from the National Cancer Institute.  

Dr. Steven Katz joined TriSalus in 2018 as Chief Medical Advisor and Chairman of the Scientific Advisory Boards. In September 2020, Steven became the first Chief Medical Officer of TriSalus. Previously, as a full-time academic surgical oncologist, he developed a reputation as a leader in solid tumor immunotherapy, cellular therapeutics, cancer biology, liver immunology and execution of immunotherapy clinical trials. His laboratory has focused on studying liver immunosuppressive cells and strategies for enabling immunotherapy in liver tumors. He also currently serves as Associate Professor of Surgery at the Warren Alpert Medical School of Brown University. His clinical expertise is in surgical therapy and multi-disciplinary management of liver tumors, pancreas tumors, sarcoma and melanoma.